786-O and ACHN cells grown as spheroids or as tumoroids derived from mice tumor samples were subjected to the FDA-approved compound sunitinib, used for first-line treatment of ccRCC or to KU-60019 plus CX-4945 (KU-CX), a combined inhibition of ATM and CK2 kinases, which has shown promising activities in a previously published drug screen [10]. Here, ATM is linked to neoplasm.